Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L Allen, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, Ian D. Lewis, MD, Miles Prince, MD, MRACMA, FRACP, FRCPA, Sonali Smith, MD, Elaine S Jaffe, MD, Susan Bates, MD

Blood (2009) 114 (22): 1657.

https://doi.org/10.1182/blood.V114.22.1657.1657

Published: 2009

Journal Articles

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, John P Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Elaine Jaffe, MD, Susan Bates, MD

Blood (2008) 112 (11): 1567.

https://doi.org/10.1182/blood.V112.11.1567.1567

Published: 2008

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

Journal Articles

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Steven Grant, MD, Daniel Sullivan, David Roodman, MD, PhD, Robert K Stuart, MD, Edward Perkins, Sarah Kolla, Viswanathan Ramakrishnan, John Wright, MD, PhD, Alexander Dimitri Colevas, M B Tombes, John D Roberts

Blood (2008) 112 (11): 1573.

https://doi.org/10.1182/blood.V112.11.1573.1573

Published: 2008

Journal Articles

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

Jeffrey E. Lancet, MD, Elliott F. Winton, MD, Robert K. Stuart, MD, Michelle Burton, RN, Christopher Cubitt, PhD, Michelle Blaskovich, John Wright, MD, PhD, Said Sebti, PhD, Daniel Sullivan, MD, MS

Blood (2008) 112 (11): 1945.

https://doi.org/10.1182/blood.V112.11.1945.1945

Published: 2008

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark H. Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, John Wright, MD, Bernadette Pulone, RN, Amalia Rincon, Paul Frankel, PhD, Stephen J. Forman, MD, Edward Newman, PhD

Blood (2007) 110 (11): 891.

https://doi.org/10.1182/blood.V110.11.891.891

Published: 2007

Journal Articles

A Radiation-Free Immune and Epigenetics Based Conditioning Regimen for Allogeneic HCT: Combination of Anti-CD3 and Romidepsin.

Nainong Li, MD, PhD, Chunyan Zhang, MD, PhD, Chia-Lei Lin, BS, Bill McCulloch, MD, John Wright, MD, Mark Kirschbaum, MD, Stephen Forman, MD, Defu Zeng, MD

Blood (2006) 108 (11): 3204.

https://doi.org/10.1182/blood.V108.11.3204.3204

Published: 2006

Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators

Blood (2006) 108 (11): 2469.

https://doi.org/10.1182/blood.V108.11.2469.2469

Published: 2006

Journal Articles

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

John Gerecitano, MD, PhD, Andre Goy, MD, Barbara MacGregor-Cortelli, OCN, Ellen Neylon, John Wright, MD, PhD, Dixie Esseltine, MD, David Schenkein, MD, Mithat Gonen, PhD, Owen A. O’Connor, MD, PhD

Blood (2005) 106 (11): 3334.

https://doi.org/10.1182/blood.V106.11.3334.3334

Published: 2005

Journal Articles

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Srdan Verstovsek, MD, Zeev Estrov, MD, Francis Giles, MD, Farhad Ravandi, MD, John Wright, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 2796.

https://doi.org/10.1182/blood.V106.11.2796.2796

Published: 2005

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

NARROW

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A Radiation-Free Immune and Epigenetics Based Conditioning Regimen for Allogeneic HCT: Combination of Anti-CD3 and Romidepsin.

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only